JNJ-49095397_product_DataBase

Bioactivity	JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 also inhibits SRC kinase family, specifically haematopoietic kinase (HCK) JNJ-49095397 shows potent anti-inflammatory effects and can be used for the research of chronic obstructive pulmonary disease (COPD) and asthma[1].
Invitro	JNJ-49095397 (RV568) (1 pg-1 μg/mL;4 h) 在 PBMCs 和 d-U937 细胞中抑制 LPS 诱导的 CXCL8 释放[1]。JNJ-49095397 (1 μg-1 g/mL; 4 h) 以浓度依赖的方式抑制 TNFα 诱导的白细胞介素 (IL)-6 和 CXCL8 的释放[1]。
In Vivo	JNJ-49095397 (RV568) (1-20 μg/mouse; intratracheal; once) 在 LPS 诱导的中性粒细胞积累小鼠模型中显示出抗炎活性[1]。 Animal Model:
Name	JNJ-49095397
CAS	1220626-82-3
Formula	C34H36N6O4
Molar Mass	592.69
Transport	Room temperature in continental US; may vary elsewhere.
Storage	Please store the product under the recommended conditions in the Certificate of Analysis.
Reference	[1]. Charron CE, et al. RV568, a narrow-spectrum kinase inhibitor with p38 MAPK-α and -γ selectivity, suppresses COPD inflammation. Eur Respir J. 2017 Oct 26;50(4):1700188.

PeptideDB